Quantum Biopharma is collaborating with Thermo Fisher Scientific to prepare a Phase 2 clinical trial of Lucid-MS, an experimental oral therapy designed to slow myelin loss, in people with progressive forms of multiple sclerosis (MS). Under the agreement, Thermo Fisher’s PPD clinical research business will support…
Adding probiotics to standard multiple sclerosis (MS) therapies may help to reduce fatigue, depression, and disability levels, as well as improve quality of life, in people with relapsing-remitting MS (RRMS), according to data from a small clinical trial. Probiotics are live microorganisms intended to support health. Compared with patients…
Tiziana Life Sciences has signed a deal with strategic partners to support a clinical trial designed to test its experimental nasal therapy foralumab in people with hard-to-treat relapsing-remitting multiple sclerosis (RRMS). Under the signed Memorandum of Understanding (MOU), the collaboration involves Tiziana, The King Abdullah International Medical Research…
The U.S. Food and Drug Administration (FDA) has given Abelzeta Pharma the go-ahead to launch an early-stage clinical trial to test its CAR T-cell therapy candidate for multiple sclerosis (MS) in people with hard-to-treat, progressive forms of the disease. According to Abelzeta, the study’s first part will enroll…
An experimental oral drug called remibrutinib outperformed the approved therapy Aubagio (teriflunomide) in reducing disease flare rates in two large, late-stage clinical trials involving people with relapsing forms of multiple sclerosis (MS). That’s according to top-line data — the studies’ first results — announced by remibrutinib’s developer…
Anti-inflammatory diets may help to ease fatigue and improve overall physical health in people with multiple sclerosis (MS), according to a new analysis of data from 10 clinical trials. Findings also indicated that anti-inflammatory diets do not substantially alter body composition, disability status, or mental health in MS patients.
While U.S. researchers believed a home-based telerehabilitation program — thought to be more convenient and accessible for patients — would prove more effective than a clinic-based one in improving walking endurance in people with multiple sclerosis (MS), data from a large clinical trial in “the Deep South” found no…
Immunic says it’s on track to announce early data by year’s end from twin late-stage trials testing vidofludimus calcium (IMU-838) — an oral therapy believed to have both anti-inflammatory and neuroprotective properties — in people with relapsing forms of multiple sclerosis (MS). The top-line results from the…
Treatment with neural stem cells — cells that have the ability to mature into supportive cells of the brain and spinal cord — showed early signs of neuroprotection in people with progressive forms of multiple sclerosis (MS), according to long-term follow-up data from a small early clinical trial. The…
Recent updates to the McDonald criteria — the internationally recognized guidelines used to diagnose multiple sclerosis (MS) — may support earlier and more accurate diagnoses. But the changes are also expected to require researchers to rethink how clinical trials testing new MS therapies are run, and better biomarkers…
